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Abstract The time-limited efficacy of reversible EGFR-TKIs
in patients with advanced non-small cell lung cancer
(NSCLC) with EGFR gene activating mutations is associated
with development of treatment resistance after some period of
therapy. This resistance predominantly results from secondary
mutations located in EGFR gene, especially T790M substitu-
tion. There is limited information available concerning the
prevalence of primary T790M mutations in patients with
metastatic NSCLC tumors before treatment with EGFR-
TKIs. The aim of work was to assess the prevalence of de
novo T790M mutations in EGFR gene in tissue samples from
NSCLCmetastatases in central nervous system (CNS) in both
chemotherapy and EGFR-TKI naive NSCLC patients. We
analyzed DNA samples isolated from paraffin-embedded tis-
sue from CNS metastases for T790M mutations using real-
time PCR and TaqMan probe against the T790M mutant
sequence. The tissue samples were taken during palliative
neurosurgery in 143 NSCLC patients. Amplification of the
T790M-specific sequence was detected in 25 patients
(17.5 %). The quantity of mutated DNA was less than 1 %
in all samples with amplification, and in vast majority (20
patients, 14 % of all samples) it was even less that 0.1 %. In 5
patients (3.5 %) quantity of mutated DNA ranged from 0.1 to
1 % and true positive results of T790M mutation presence in
these patients were most possible. Amplification of this se-
quence was not concurrent with common EGFR mutations
and was not associated with sex, smoking status and patho-
logical type of cancer. There is a possibility to detect the
primary T790M mutation in brain metastases of NSCLC in
EGFR-TKIs naïve patients.
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Introduction
Various genetic disorders, such as mutations as well as ge-
nome rearrangements in non-small-cell lung cancer (NSCLC)
cells are currently the subject of intensive research. Whilst the
detection of the genetic abnormalities could enable to develop
the new target for different targeted therapies, the detailed
descriptions of those changes could help to understand of
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mechanisms of resistance for already existing therapies. Ge-
netic disorders in rare cell clones from heterogenic NSCLC
tumors and their possible role in designing of molecular
targeted therapy in the patients not responding for modern
therapies are becoming of great interest.
T790M mutation in EGFR gene seems to be one of the
most important genetic abnormalities involving the resistance
for reversible epidermal growth factor receptor tyrosine ki-
nases inhibitors (EGFR-TKI)—erlotinib and gefitinib in
NSCLC patients [1–3]. T790M mutation is detected with
highest prevalence in patients with common activating muta-
tions of EGFR gene (L858R in exon 21 and deletions in exon
19) after long-term and initially effective treatment with
EGFR-TKIs. Based on this finding it was considered that
T790M is a secondary resistance mutation resulting from
EGFR-TKIs therapy. Recently it was suggested that substitu-
tion in codon 790 of exon 20 EGFR gene could be visible
primary in coincidence with other activating mutations of
EGFR gene (5–30 % NSCLC patients) [4–6] and secondary,
after primary EGFR disorders, mainly L858R mutation (app.
50 % patients) [2, 5–7].
Although T790M mutation plays a leading role in emer-
gency of reversible EGFR-TKIs resistance, the mechanism of
its appearance is still unclear. Whilst it was suggested, that
T790M mutation is driven by EGFR-TKIs therapy, recently
this is postulated, that this mutation is present at the very
beginning in a rare clone of NSCLC cells even in EGFR-
TKIs naive patient. The cells with T790M mutation are not
detectable during primary EGFR status assessment due to
very low sensitivity of available molecular biology methods.
Then, as results of effective EGFR-TKI treatment, the larger
clone with L858R mutation or deletions in exon 19 in EGFR
gene is eliminated and treatment-resistant cell clones, contain-
ing wild type EGFR gene or T790M mutation can proliferate
[3, 5, 6]. In those cases T790M mutations could be detectable
in the same tumors containing L858R substitutions or dele-
tions in exon 19, but on distinct cell clones.
Although there is an increasing knowledge about preva-
lence and detectability of activating mutations of EGFR gene
in NSCLC metastatic changes in central nervous system
(CNS), the primary mutations, connected with molecular
targeted therapy resistance in patient with distant metastases
remain unresolved [8, 9]. The aim of work was to assess the
sensitive method, enabling detections of cells with T709M
mutations, to estimate their percentage as well as to assess the
prevalence of primary T790M mutation in metastatic NSCLC
changes in CNS.
Material and Method
To assess the prevalence of T790M mutation in exon 20 of
EGFR gene we retrospectively analyzed the paraffin-
embedded material from cancer tissue taken from CNS
Fig. 1 Amplification curves for DNAwith T790Mmutation diluted with control DNA and control DNA alone: 1–50 %, 2–25 %, 3–20 %, 4–10 %, 5–
5 %, 6–2 %, 7–1 %, 8—control DNA
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metastases from totally 143 NSCLC patients (99 male and 44
female) at the age ranged 38–81 (mean: 59.8±8.8 years). The
patients underwent neurosurgery palliative procedure in rou-
tine manner. The patients were chemotherapy as well as
EGFR-TKI naïve.
Based on histological evaluation in 61 (42.6 %) patients
adenocarcinoma was diagnosed, in 23 (16.1 %) patients
squamous cell and in 21 (14.7 %) patients large cell
carcinoma. In 38 (26.6 %) patients NSCLC remained
“not otherwise specified” (Table 2). Median of overall
survival (OS) since diagnose to death was 9.2 months
(range: 0.1–78.2 months).
To isolate DNA samples from paraffin-embedded NSCLC
tissue QiampDNAFFPE Tissue Kit (Qiagen, USA) was used.
DNA concentration was measured in Biofotometr Plus spec-
trophotometer (Eppendorf, Germany). The substitution
T790M in exon 20 in EGFR gene was assessed by real-time
PCR using specific for mutated EGFR gene molecular probes
TaqMan (Applied Biosystem). Real-time PCR was conducted
in Eco Real-Time PCR System (Illumina) according to Muta-
tion Detection Assays Protocol (Applied Biosystems), deliv-
ered by manufacturer of TaqMan® reagents. Additionally, for
each sample the reference gene amplification was performed
using molecular probes complementary for non-mutated
EGFR gene part (positive intrinsic control). For negative
control DNA isolated from peripheral blood leukocytes of
healthy subjects was used.
Furthermore, in analyzedmaterial the prevalence of L858R
substitution in exon 21 and deletion in exon 19 of EGFR gene
were assessed using the following techniques: PNA-LNA
PCR Clamp (for both common EGFR gene mutations),
ASP-PCR (for L858R substitution) and PCR and analysis of
the length of amplified DNA chains (for deletions in exon 19).
The presence of L858R mutation and deletion in exon 19 of
EGFR gene were confirmed using direct sequencing method.
This method was not used for the confirmation of T790M
substitution due to its low sensitivity (requiring above >50 %
cells with mutated DNA).
To assess the sensitivity of real-time PCR method used for
detection of T790M substitution in EGFR gene the series of
dilutions of DNA isolated from H1975 cell line containing
substitutions T790M and L858Rwas prepared. Mutated DNA
was diluted with DNA isolated from peripheral blood leuko-
cytes from healthy subjects, which concentration was identical
than mutated DNA. There were the following mutated DNA
concentrations: 50, 25, 20, 10, 5, 2 and 1 %. The result of real-
time PCR and amplification curves for analyzed dilutions are
presented on Fig. 1.
Again, in the second part of the experiment the series of
dilutions of DNA isolated from H1975 cell line was prepared,
but with higher DNA dilutions than in the first part: 10 %,
5%, 2%, 1%, 0,1 %, <0,1%. The result of real-time PCR and
amplification curves for analyzed dilutions are presented on
Fig. 2.
Fig. 2 Amplification curves for DNAwith T790Mmutation dilutedwith control DNA and control DNA alone: 1–10%, 2–5%, 3–2%, 4–1%, 5–0,1%,
6–<0,1 %
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Results
Ninemost common activatingEGFR genemutations (6.29%)
were detected in CNS metastases of NSCLC: 3 deletions in
exon 19 (2.1%) and 6 substitutions L858R (4.2%). In none of
them the amplification of sequence containing the T790M
mutation was detected (no signal from T790M mutation-
specific probe).
Based on real-time PCR results the presence of amplifica-
tion DNA product containing T790M mutation was revealed
in 34 patients (23.8 % of evaluated group). In each case the
amplification of reference gene was also observed (positive
intrinsic control). During 45 cycles-real-time PCR the ampli-
fication of negative control (non-mutated DNA) was shown,
usually after 43, cycle of PCR reaction, which possible result-
ed from unspecific binding of the probe to analyzed DNA
sample. Taken the number of cycles, after which amplification
of negative control occurred as a cut-off point between false
positive and false negative results, the appearance of amplifi-
cation product was judged as unspecific in 9 patients (6.3 %).
Figure 3 presents the result of T790M mutation in 2 patients
with presence of amplification product of DNA sequence
containing T790M mutation in EGFR gene.
During second part of the experiment all samples were
tested for T790M substitution with lowering number of reac-
tion cycles to 42. Because the negative control was usually
amplified after 43. cycle we determine cut off point in 42.cy-
cle. Upon those conditions the amplification product of
mutated DNA sequence was detected in 25 patients
(17.5 %), whereas the amplification of negative control was
not observed.
During the next part the percentage of copies of mutated
EGFR gene with T790M mutation among wild-type DNA
copies was estimated. Firstly, the amplification curves for the
series of dilutions of DNA from H1975 cell line (used for
calibration) were compared with amplification curves for
cases with detected specific product of reaction for T790M
mutation. Secondly, estimated content of mutated DNA in
analyzed samples was calculated, using the formula:
% mutated DNA ¼ 1=2ΔΔCt*100%
where: ΔΔCt=ΔCt (analyzed sample)−ΔCt (calibrator). To
calculate ΔCt for analyzed sample and calibrator the differ-
ence between threshold values of real-time PCR (Ct) was
calculated, using the formulas:
ΔCt analyzed sampleð Þ ¼ Ct of analyzed gene−Ct of reference gene
ΔCt calibratorð Þ ¼ Ct of calibrator−Ct of reference gene
Based on mathematical analysis, the content of mutated
DNA in all positive samples was assessed as <1 % (Table 1).
Table 2 presents estimated content of mutated DNA in ana-
lyzed material.
Fig. 3 Amplification curves for DNAwith T790M mutation: curves 1 and 2 – patients, curve 3—control DNA
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Additionally it was found, that prevalence of real-time PCR
products specific for DNA sequence with T790M mutation
was similar in male and female patients, smokers and non-
smokers and across different histological NSCLC types
(Table 2).
Discussion
The role of T790M mutation, particularly its presence in
patients before EGFR-TKIs treatment is still controversial
being a subject of intensive discussions. Mechanism of
achieving resistance to erlotinib and gefitinib remains unclear.
The recent reports confirmed, that T790M substitution could
be detected in EGFR-TKIs naïve patients independently of
other EGFR gene mutations (predominantly L858R substitu-
tion and deletions in exon 19). This finding supports the
observations, that coincidence of driving mutations is exqui-
sitely infrequent.
Clone of cancer cells with some of driving mutations could
be very small in heterogenic tumors, thus it could not be
detected by methods like direct DNA sequencing. During
EGFR-TKIs therapy the majority of cells with activating
EGFR mutations undergo massive apoptosis leading to ex-
posing and predominance of treatment-resistant subpopula-
tion, e.g. with T790Mmutation, which could be easier detect-
ed with standard molecular biology methods [3, 5].
The development of molecular biologymethods, especially
increased sensitivity of detection, supports mentioned above
assumptions. Maheswaran et al. assessed tissue material from
26 EGFR-TKIs naïve patients with common activating EGFR
gene mutation for T790M mutation. Using of SARMS-PCR
technique with Scorpion probes in material with low content
of mutated DNA allowed detecting substitutions in 10 patients
(38 % analyzed sample). Appearance of product amplification
after high number of cycles of PCR reaction used in this trial
suggests, that mutation is present only in small tumor cells
clone. Additionally, the sequencing of one of the PCR reaction
products identified only one DNA copywith T790Mmutation
among 500 alleles of wild-type EGFR gene [4].
Based on this findings showing the presence of T790M
mutation in very limited cancer cell clones, for detection of
exon 20 of EGFR gene mutations Oh et al. used very sensitive
PNA Clamp PCR (peptide-nucleic acid-clamp PCR) method,
allowing detection of mutation even if it is in less than 1 %
mutated cells. The mutation was revealed in 12 of 147 un-
treated patients (8.2 % of analyzed sample). However it was
unselected group according to histological findings and EGFR
gene status [6].
The very recent studies of Su et al. confirmed the theory
how the T790Mmutation becomes detectable. To confirm this
mutation the authors used very sensitive MALDI-TOF MS
(highly sensitivity matrix-assisted laser desorption ionization-
time of flight mass spectrometry) method and next-generation
sequencing. Using very sensitive methods made possible
Table 2 The prevalence of am-
plification of mutated EGFR gene
fragment containing T790M mu-
tation in CNS metastases of
NSCLC
Clinical measures Prevalence of
T790M mutation
(<1 % of mutated
DNA)
Prevalence of T790M
mutation (1–0.1 % of
mutated DNA)
Prevalence of T790M
mutation (less than 0.1 %
of mutated DNA)
Total cases (n=143) 25 (17.5 %) 5 (3.5 %) 20 (14 %)
NSCLC-NOS (n=38) 10 (26.4 %) 2 (5.3 %) 8 (21.1 %)
Adenocarcinoma (n=61) 8 (13.1 %) 1 (1.6 %) 7 (11.5 %)
Squamous cancer (n=23) 4 (17.4 %) 0 4 (17.4 %)
Large-cell cancer (n=21) 3 (14.2 %) 2 (9.5 %) 1 (4.7 %)
Sex
Female (n=44) 9 (20.5 %) 1 (2.3 %) 8 (18.2 %)
Male (n=99) 16 (16.1 %) 4 (4 %) 12 (12.1 %)
Smoking status
Smokers (n=86) 17 (19.8 %) 3 (3.5 %) 14 (16.3 %)
Non-smokers (n=32) 4 (12.5 %) 1 (3.1 %) 3 (9.4 %)
Lack of data (n=25) 4 (16 %) 0 4 (16 %)
Table 1 Estimated content of DNA with T790M mutation in analyzed
material
Content of mutated
DNA in analyzed material
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estimation of prevalence of T790M mutation in patients be-
fore and after cessation of EGFR-TKIs therapy. Mutation was
detected in 27 among 107 EGFR-TKIs naive patients
(25.2 %), whereas direct sequencing method led to detection
of only 3 patients with T790M substitution (2.8 %). In group
of 73 EGFR-TKIs treated patients T790M mutations were
detected in 23 patients (31.5 %), whereas using direct se-
quencing method only in 2 patients (2.7 %). Additionally 12
samples from patients after discontinuation of EGFR-TKIs
therapy due to progression were assessed. T790M mutation
was confirmed in up to 10 patients (83.3 %). The study results
support the conclusion, that primary T790M mutation is even
more common than previously assumed. Additionally the
authors concluded, that percentage of cells with primary
T790M substitution is lower than in tumors after EGFR-
TKIs therapy [5].
Noteworthy, according to different researchers, percentage
of patients with de novo detected T790M mutation ranges
widely from 1 to 38 %, what is possible depending on sensi-
tivity of methods used for detection and sample selection
[4–6, 10]. Furthermore, up to now it was conducted any study
worldwide analyzing primary T790M mutations in NSCLC
metastatic tumors to CNS or to other organs.
Our findings confirm, that primary T790M mutation is
more common in NSCLC patients than it was suggested
previously and that it could be detected in NSCLC metastatic
changes in CNS. Detection of amplification product for mu-
tated DNA sequence with T790M mutation was possible
using real-time PCR—the most frequently used molecular
biology method for diagnostic purposes. Furthermore, the
study involved unselected population regarding histological
finding and smoking status. It should be highlighted, that in
each sample with amplification of EGFR gene region with
T790M mutation the content of mutated DNA was less than
1 %, and in majority of cases (80 %) it was even below 0.1 %.
Firstly, it seems to be impossible to repeat our finding using
neither direct DNA sequencing method nor routine methods
for in vitro diagnostics (it is assumed, that sensitivity of those
methods should not allow to detect mutations when DNA
content is below 10 %). Secondly, our finding should be
treated with caution because they are very difficult to verify.
It appears that the results of detection of T790M mutation are
considerable within the range of DNA content between 0.1
and 1 % of analyzed material. Taking into consideration the
fluorescence appearance from T790M mutation-specific
probe even using wild-type DNA for real-time PCR, reliabil-
ity of results from samples with DNA content below 0.1 %
could be questioned (PCR products misamplified by polymer-
ase). According to this it should be noted, that in our study,
similarly to Maheswaran et al. study, we used high number of
PCR cycles, after which amplification product was detectable.
It is not routinely used for EGFR gene mutation diagnostic in
clinical practice to avoid false positive results. Therefore, we
are not sure that results below 0.1 % of mutated DNA were
valid.
The possibility of detection of T790M mutation in EGFR-
TKIs naive patients forces to expand the diagnostics of EGFR
gene status during qualification for erlotinib or gefitinib treat-
ment and to consider the new therapy modalities in carriers of
this mutation. The new therapy methods, which could be
effective in patients with T790M mutation includes irrevers-
ible EGFR-TKIs (afatinib, neratinib). In LUX-Lung 1 study in
patients after failure of erlotinib or gefitinib treatment with
afatinib led to partial responses and prolongation of
progression-free survival compared to placebo to 3,3 months
[11, 12]. Recently the studies are conducted with combining
of irreversible EGFR-TKI and monoclonal antibody against
extracellular domain of EGFR – cetuximab. In study conduct-
ed by Janjigian et al. all patients treated with afatinib and
cetuximab achieved disease control, and part of them (36 %)
partial response. Additionally, 4 of 13 patients (31 %) with
T790M mutations gained confirmed partial response after
combined therapy with monoclonal antibody and irreversible
EGFR-TKI [13].
Currently, reversible EGFR-TKIs therapy is not contrain-
dicated in carriers of T790M mutations. Furthermore, this
mutation as well as other driving EGFR genemutations, could
be favorable predictive factor for EGFR-TKIs therapy. Recent
studies indicated, that substitution T790M in EGFR-TKIs
naïve patients could be connected to better prognosis and
longer time to EGFR-TKIs therapy failure. In patients with
T790M mutation median time do therapy failure was longer
(9 months) than in patients without mutations (7 months).
Additionally, median progression free survival was even lon-
ger in patients with higher percentage of mutated T790M
allele than in patients with lower number of EGFR gene
copies with T790Mmutation [14]. Some reports deny the role
of T790M mutation in carcinogenesis, since this mutation is
more common in advanced NSCLC than in early stage tumors
[10].
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